Key result
Systemic and catheter-directed thrombolysis for acute pulmonary embolism are reviewed in the context of current clinical evidence and societal guidelines.
Why the study?
Acute pulmonary embolism is a potentially fatal illness with high early mortality, prompting a review of contemporary evidence and guidelines for systemic and catheter-directed thrombolysis.
This article provides a review of current clinical evidence and societal guidelines for systemic and catheter-directed thrombolysis in acute pulmonary embolism.
Novel PE mortality timing supports urgent triage; leaves open targeted interventions pending validation.
Venous thromboembolism (VTE) is the third most common cause of cardiovascular disease after myocardial infarction and stroke. Population-based studies estimate that up to 94,000 new cases of pulmonary embolism (PE) occur in the United States annually with an increasing incidence with age. Mortality from PE is the greatest in the first 24 hours, with a decreased survival extending out 3 months. Thus, acute PE is a potentially fatal illness if not recognized and treated in a timely manner. Contemporary management includes systemic anticoagulation, thrombolysis, catheter-based procedures, and surgical embolectomy. This article reviews current clinical evidence and societal guidelines for the use of systemic and catheter-directed thrombolysis for treatment of acute PE.
No takes yet. Share an insight, caveat, or question.
Todoran et al. (2021) conducted a review in Acute Pulmonary Embolism. Systemic and catheter-directed thrombolysis was evaluated. Systemic and catheter-directed thrombolysis for acute pulmonary embolism are reviewed in the context of current clinical evidence and societal guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: